S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Stock ideas from the 2024 Microcap Conference
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
How major US stock indexes fared Friday, 2/23/2024
Closing prices for crude oil, gold and other commodities
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
Warren Buffett tells investors to ignore Wall Street pundits while paying tribute to Charlie Munger
MarketBeat Week in Review – 2/19 - 2/23

Allogene Therapeutics (ALLO) Stock Forecast & Price Target

$4.54
+0.18 (+4.13%)
(As of 02/23/2024 ET)

Allogene Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings

Analysts' Consensus Price Target

$15.29
236.82% Upside
High Forecast$31.00
Average Forecast$15.29
Low Forecast$6.00
TypeCurrent Forecast
2/24/23 to 2/24/24
1 Month Ago
1/25/23 to 1/25/24
3 Months Ago
11/26/22 to 11/26/23
1 Year Ago
2/24/22 to 2/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$15.29$15.29$15.35$20.27
Predicted Upside236.82% Upside211.25% Upside176.62% Upside115.40% Upside
Get Allogene Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.


ALLO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALLO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Allogene Therapeutics Stock vs. The Competition

TypeAllogene TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.73
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside236.82% Upside1,898.84% Upside7.52% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/19/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$12.00 ➝ $10.00+212.50%
1/5/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
1/5/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform
12/8/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$7.00+177.78%
9/25/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$11.00 ➝ $9.00+146.57%
8/3/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$28.00+497.01%
7/12/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$20.00 ➝ $18.00+209.28%
5/4/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$8.00 ➝ $7.50+31.12%
4/17/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$15.00+209.92%
3/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/21/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$6.00+11.73%
3/1/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$32.00 ➝ $22.00+247.00%
3/1/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$35.00 ➝ $31.00+388.19%
3/1/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$18.00 ➝ $15.00+136.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:01 AM ET.












ALLO Price Target - Frequently Asked Questions

What is Allogene Therapeutics's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Allogene Therapeutics stock is Moderate Buy based on the current 3 hold ratings and 8 buy ratings for ALLO. The average twelve-month price prediction for Allogene Therapeutics is $15.29 with a high price target of $31.00 and a low price target of $6.00. Learn more on ALLO's analyst rating history.

Do Wall Street analysts like Allogene Therapeutics more than its competitors?

Analysts like Allogene Therapeutics more than other Medical companies. The consensus rating score for Allogene Therapeutics is 2.73 while the average consensus rating score for medical companies is 2.68. Learn more on how ALLO compares to other companies.

Is Allogene Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Allogene Therapeutics's stock had 1 downgrade by analysts.

Does Allogene Therapeutics's stock price have much upside?

According to analysts, Allogene Therapeutics's stock has a predicted upside of 211.25% based on their 12-month stock forecasts.

What analysts cover Allogene Therapeutics?

Allogene Therapeutics has been rated by Citigroup, Guggenheim, HC Wainwright, and JMP Securities in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ALLO) was last updated on 2/24/2024 by MarketBeat.com Staff